# Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease

Study · id `cardio:ct-nct06925698` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06925698](<https://clinicaltrials.gov/study/NCT06925698>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06925698

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 110 participants.

## Technical summary

Registry record NCT06925698. Randomized; quadruple masking; primary purpose treatment. Start 2025-04-30 (anticipated); primary completion 2027-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 110 participants (planned count; ClinicalTrials.gov record NCT06925698, source copy `cardio:ctgov-nct06925698-2025-04-13`, retrieved 2026-10-31)
- Planned start: 2025-04-30 (anticipated) (ClinicalTrials.gov record NCT06925698, source copy `cardio:ctgov-nct06925698-2025-04-13`, retrieved 2026-10-31)
- Primary completion: 2027-04-01 (anticipated) (ClinicalTrials.gov record NCT06925698, source copy `cardio:ctgov-nct06925698-2025-04-13`, retrieved 2026-10-31)
- Completion: 2028-04-01 (anticipated) (ClinicalTrials.gov record NCT06925698, source copy `cardio:ctgov-nct06925698-2025-04-13`, retrieved 2026-10-31)
- Countries: Türkiye (ClinicalTrials.gov record NCT06925698, source copy `cardio:ctgov-nct06925698-2025-04-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06925698-2025-04-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease
- Acronym: BETTER
- Condition: Behcet Disease
- Condition: Behcet Disease and Vascular Involvement
- Condition: Deep Venous Thromboses
- Condition: Post Thrombotic Syndrome
- Intervention (Drug): Placebo plus immunosuppression
- Intervention (Drug): Rivaroxaban plus immunosupression
- Lead sponsor: Marmara University
- Lead sponsor class: OTHER
- Collaborator: Health Institutes of Turkey
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)

## Provenance

Content hash: a485f690091e60c65bee22af12c318c52464dfa3ec4992d6c2ed48811a6b3139
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
